Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
New England Journal of Medicine · 17.07.2025 · 393 (3) · 217-230
DOI: 10.1056/nejmoa2503701 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 17.07.2025. Verfasst von Yelena Y Janjigian und 27 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms. Die Arbeit wurde bisher 393-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York.
- Krankenhaus Nordwest, University Cancer Center (UCT) Frankfurt, and Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany.
- Department of Gastrointestinal Medical Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York.
- Department of Gastroenterology/Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
ORCID-Profile: Victor Castro Oliden, Akihito Kawazoe
Förderung
- AstraZeneca
Zitieren
APA
Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L., Oh, D. Y., Omori, T., Moehler, M., Garrido, M., Oliveira, S. C. S., Liberman, M., Oliden, V. C., Smyth, E. C., Stein, A., Bilici, M., Alvarenga, M. L., …, & MATTERHORN Investigators (2025). Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. New England Journal of Medicine, 393(3), 217-230. https://doi.org/10.1056/nejmoa2503701
Vancouver
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. New England Journal of Medicine. 2025;393(3):217-230. doi:10.1056/nejmoa2503701
BibTeX
@article{Janjigian2025,
author = {Janjigian, Yelena Y and Al-Batran, Salah-Eddin and Wainberg, Zev A and Muro, Kei and Molena, Daniela and Van Cutsem, Eric and Hyung, Woo Jin and Wyrwicz, Lucjan and Oh, Do-Youn and Omori, Takeshi and Moehler, Markus and Garrido, Marcelo and Oliveira, Sulene C S and Liberman, Moishe and Oliden, Victor Castro and Smyth, Elizabeth C and Stein, Alexander and Bilici, Mehmet and Alvarenga, Maria Lorena and Kozlov, Vadim and Rivera, Fernando and Kawazoe, Akihito and Serrano, Olivier and Heilbron, Eric and Negro, Alejandra and Kurland, John F and Tabernero, Josep and MATTERHORN Investigators, MATTERHORN Investigators},
title = {Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {3},
pages = {217--230},
doi = {10.1056/nejmoa2503701}
}
EUVIMED